Madecassoside - CAS# 34540-22-2 ydrate) Smiles: COC1=CC(=CC=C1O)[C@H]1OC2=CC(=CC=C2O[C@@H]1CO)[C@H]1OC2=CC(O)=CC(O)=C2C(=O)[C@@H]1O

Smiles: COC1=CC(=CC=C1O)[C@H]1OC2=CC(=CC=C2O[C@@H]1CO)[C@H]1OC2=CC(O)=CC(O)=C2C(=O)[C@@H]1O

Bmax = 213 fmol/mg protein)

27)15-4-3-9-20-16(15)13-5-7-14(8-6-13)18-24-22-11-29-18/h3-11H

Overexpression of specific Src kinases is also associated with the imatinib-resistant CML phenotype

as evidenced by a 23% reduction in epidermal thickness

Madecassoside - CAS# 34540-22-2 ydrate) Smiles: COC1=CC(=CC=C1O)[C@H]1OC2=CC(=CC=C2O[C@@H]1CO)[C@H]1OC2=CC(O)=CC(O)=C2C(=O)[C@@H]1OMadecassoside is a pentacyclic triterpene isolated from Centella asitica (L.), as an anti inflammatory, anti oxidative activities and anti aging agent. In vitro: Madecassoside exhibit significant anti proliferative and anti invasive effect in HGF induced HepG2 and SMMC 77 cells. Madecassoside inhibit the HGF induced activation of cMET PKC ERK1 2 COX 2 PGE2cascade. [1] In vivo: Administration of madecassoside, p. o. , exhibit a direct anti PF effect in